Grifols, S.A. (GRF.MC)
| Previous Close | 9.36 |
| Open | 9.28 |
| Bid | 9.40 x 0 |
| Ask | 9.39 x 0 |
| Day's Range | 9.26 - 9.46 |
| 52 Week Range | 6.36 - 15.92 |
| Volume | |
| Avg. Volume | 4,249,227 |
| Market Cap | 5.63B |
| Beta (5Y Monthly) | 0.67 |
| PE Ratio (TTM) | 104.62 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jun 03, 2021 |
| 1y Target Est | N/A |
- Bloomberg
Short Seller Gains on Grifols Bet That Tripped Elliott Spinout
(Bloomberg) -- A well-publicized short bet by General Industrial Partners on Spanish company Grifols SA helped the hedge fund earn double-digit gains while bullish wagers on the same stock caused losses to former Elliott Management trader Franck Tuil.Most Read from BloombergMicrosoft’s Xbox Is Planning More Cuts After Studio Closings‘Seriously Underwater’ Home Mortgages Tick Up Across the USAmericans Are Racking Up ‘Phantom Debt’ That Wall Street Can’t TrackMarjorie Taylor Greene Finally Got Wha
- Reuters
Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper
MADRID (Reuters) -Spanish drug maker Grifols, battling a plunge in its share price this year, plans to add independent directors to its audit and compensation committees to improve its governance, its chairman said in a newspaper interview published on Sunday. Grifols' market value has shed billions of euros since short-sheller Gotham City Research released three reports in early January accusing the company of overstating earnings and understating debt. Grifols has repeatedly denied the claims.
- Reuters
Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake
Spanish drug maker Grifols plans to meet its debt payments in 2025 with the proceeds of new senior secured notes and the sale of its 20% stake in Shanghai RAAS to Haier Group, it said on Wednesday. Grifols did not specify the amount due next year. Since January, the Spanish drug maker's debt sustainability has been questioned by short seller Gotham City Research.
